The licensed technology potentially allows for the more efficient triggering of RNA interference (RNAi) and includes the use of shRNAis either delivered as RNA compositions or encoded by DNA constructs. Patents covering this technology are currently pending. Financial terms were not disclosed for competitive reasons.
“With this license for all human therapeutic areas, we gain the well-validated advantage of shRNAi – which is reported to be up to 10- to 100-fold more potent compared with standard siRNA,” said Tod Woolf, RXi’s president and CEO.